Ovarian cancer drug safety check: what side effects did 354 patients report?
NCT ID NCT05021562
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at side effects of the drug niraparib (Zedula) in 354 people with ovarian cancer. Participants took niraparib capsules once a day as part of their normal care, and doctors recorded any side effects for one year. The main focus was on serious side effects like low blood cell counts, high blood pressure, and lung problems. This was an observational study, meaning the drug was not being tested for how well it works, only for safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Takeda Selected Site
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?